Abintus Bio is pursuing in vivo CART products that directly reprogram immune cells from within their native environment using a proprietary viral platform technology. Leveraging $275M in prior technology advancement, the founding team has the relevant playbook and 75 years of collective in vivo virus know how from discovery to pre-launch.

Active Life develops and commercializes life science research and diagnostic tools based on renowned UC Santa Barbara Professor Paul Hansma's latest invention, Reference Point Indentation (RPI). RPI is a patented technology that provides life scientists and doctors the previously impossible ability to measure the physical properties of biological tissues in vivo, without the need for an invasive biopsy. Physical properties of tissues are a known, direct indicator of various states of debilitating diseases, but conventional tools available to measure physical properties are confined to specialized laboratories and operation by trained technicians, severely preventing wide-spread use.

Actuate Therapeutics is currently advancing a novel best-in-class GSK-3β inhibitor into the clinic for oncology and fibrotic diseases Across multiple institutions, researchers have conducted studies of 9-ING-41 with compelling results. The IND was approved in 1Q18 and a groundbreaking Phase 1/2 study is ready to initiate in 2018.

Larada Sciences is a Salt Lake City, Utah-based company dedicated to the eradication of head lice. It has built the world's largest network of lice-removal professionals. Its flagship product, AirAllé® (pronounced air-a-lay) is an FDA-cleared medical device that kills head lice and 99.2 percent of lice eggs in a single, one-hour treatment. Formerly called LouseBuster, the AirAllé device is used by lice-removal professionals around the world to provide a safe, fast and highly effective lice treatment. The company is a spin-out from the University of Utah that was formed in 2006.  

Simple, Secure Occlusion. Amsel Medical's CE mark and FDA cleared SCureClamp™ with Interdigitation Occlusion Technology (iDOT™) is designed to easily and securely close vessels – veins, arteries, and tubular structures – during surgical and interventional procedures.

Anabios deploys assays and develop databases for the testing of efficacy and safety of drugs in development.

Apeel Sciences develops plant-derived technology to help USDA organic and conventional fresh food providers maintain quality, reduce waste and ensure an abundant future for our planet.

With Arima Genomics Discover the Power of 3D Genomics to Unlock New Biological Insights, Drive Biomarker Breakthroughs, Identify Therapeutic Targets and Improve Human Health. Gain unparalleled access to the sequence + structure of any genome. Reveal how spatial and temporal changes in chromatin conformation alter gene regulation and cellular function.

Ataxia Biologics is a clinical-stage biotechnology company that is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. Avaxia’s proprietary oral antibody platform makes direct delivery of antibodies to the GI tract possible by overcoming some of the traditional limitations of antibody therapeutics. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia is developing gut-targeted therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome, and oral mucositis.

CapBio has developed technologies to simplify diabetes management and improve the quality of life for millions of diabetics. The Company’s first product is a patented Continuous Subcutaneous Insulin Infusion (CSII) set and patent pending insertion device that improve the effectiveness of insulin delivery and double the duration of use.

CardioCreate is pioneering a bold, new approach to heart disease.  Instead of treating the symptoms of heart attack and heart failure, our genetically-engineered stem cells replace damaged heart tissue with healthy, functional heart tissue.  Heart disease is the greatest single component of healthcare costs today, and this regenerative approach could dramatically reduce those expenditures.  Our mission is to advance this promising technology through preclinical development and clinical trials so that it can improve the lives of millions of patients.

Carterra  (formerly Wasatch Microfluids) is dedicated to the advancement of label-free biomolecular interaction analysis, with a passionate focus on throughput and quality. it is a Fully Integrated High Throughput mAb Characterization Platform.

Ceresti Health Inc. We leverage and support family caregivers to improve cost and quality outcomes for multi-chronic patients, beginning with those that have Alzheimer's Disease and other dementias. Our customers are at-risk providers and payers, including Medicare Advantage health plans.

Approximately 2.4 million diabetic foot ulcers are diagnosed each year in the U.S, many progressing to lower limb amputation. It is estimated that the U.S. healthcare costs for treating diabetic foot ulcers and related amputations exceed $10 billion per year. Treating diabetic foot ulcers that have continually failed standard care therapies is a frustrating problem. CureCare has been developing and testing a treatment therapy system, O2Misly™, which actually heals these, failed wounds. CureCare has been conducting an IRB approved study using O2Misly™ on chronic diabetic foot ulcer patients at two clinics in southern California. O2Misly™ technology is a new method, a medical device that offers a combination, adjunctive therapy to the standard of care. O2Misly™ provides oxygen infused under micro tension in a closed chamber blended with a mist, which also delivers an antimicrobial to the affected area. O2Misly™ technology is producing remarkable results. Patients that had failed various standard of care therapies and have had open wounds for years are seeing their wounds finally heal. CureCare Technologies, Inc. is excited to bring the O2Misly™ Wound Treatment System to a patient population that has faced the consequences of a debilitating disease with little hope of winning their battle.

Deep Blue is developing a novel hernia mesh to address the unacceptably high rate of hernia recurrence. Our surgeon-invented mesh design with integrated suture-like extensions eliminates the key point of failure for conventional mesh fixation and provides 275% greater anchor strength. Our T-Line Mesh will reduce hernia repair failures.    

Dodo OmniData, Inc.: Long-term data storage gap is a very large, growing market sufficient technology solutions. Dodo has patented an approach exploits the high density, long-term durability advantages of DNA. Leveraging this with semiconductor fabrication the resulting solution can be 10x cheaper and at least 2,000x more data dense than current technologies.

Elemeno is a B2B SaaS that transforms client practices into concise, actionable guides delivered just-in-time at the point of need. The allows healthcare institutions to drive frontline adoption of priority practices at scale, improving consistency and outcomes. No PHI. No IT integration. Easy to start. Land and expand.

Elysium Therapeutics, Inc. Elysium is executing a capital-efficient strategy to disrupt the $10B+ Rx opioid pain market by developing a new class of Rx opioids that are designed to (i) protect against fatal oral and non-oral overdose; (ii) disrupt the progression to Rx and illicit opioid abuse and addiction; and (iii) provide patients with effective pain relief.

Eumentis Therapeutics is Developing Novel Therapeutics to treat High Value Neurodevelopmental and Neurodegenerative Diseases.

Improve your research. ExpressCells uses CRISPR and its patented plasmid system to create knock-in cell lines that fit your experiments.

Eyedaptic is a software technology company addressing unmet needs and is focused on development of visually assistive Augmented Reality solutions. Targeting over a $20 billion market, these devices are designed to offer visually deficient consumers a non-invasive, mobile visual aid to address retinal field of vision impairments.

Forge Therapeutics, Inc is a biotechnology company discovering and developing novel therapeutics using an innovative chemistry platform targeting metalloproteins. Forge uses a proprietary approach combining bioinorganic (study of metals in biology) and medicinal chemistry to generate selective inhibitors of this large class of targets.

 Gemmus is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases. Using a novel, host-directed approach, we target the underlying cause of debilitating symptoms associated with influenza and 'influenza-like-illness' (ILI) by modulating the natural immune response to the disease. We are committed to developing “first-in-class, best-in-class” products that meet a major medical need. Gemmus Pharma was founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. The company has applied for and received an SBIR(NIH) and a QTDP competitive grant.  Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.

HAI Solutions has developed a unique portfolio of medical devices addressing the growing plague of contamination within the operating room, emergency room and intensive care units.

Hawthorne Effect, Inc: With custom technology and a gig economy network of specialized health professionals, HE makes follow-up visits more accessible for patients. The value to clinical investigators / pharma / medtech is improvement of quality, quantity, timeliness and security of data needed by innovators and, for patients, ease of participation.

HealthInReach is a free service that helps people find the lowest prices from qualified dentists and doctors, then easily book appointments online. By conveniently scheduling your appointment here, you may save up to half or more off the typical price. There are more than 1.6 million appointments available at Health In Reach and we offer descriptions and prices for nearly 50,000 specific procedures. Today, there are 130 million Americans who pay for dental care out-of-pocket and tens of millions more who pay for elective medical procedures in cash. Yet, most people won’t know the cost until they get a huge bill. When possible, we don’t think it makes senses to see a doctor without knowing what you’re going to get or how much it’ll cost. Health In Reach is focused on helping eliminate surprises and making healthcare more affordable.

Heart Health Intelligence (HHI) will significantly reduce the cost of heart failure by preventing hospital readmissions through a toilet seat-based cardiovascular monitoring system and a mid-level provider run monitoring service. HHI will transform the healthcare system by enabling the transition from reactive to proactive care.

HOLOCLARA IS WORKING TO PROVIDE RELIEF FOR MILLIONS OF PEOPLE WITH ALLERGIC AND AUTOIMMUNE DISEASES. USING WORMS.

iDentical is leveraging the latest 3D technology to revolutionize the $21B tooth replacement industry with its patent pending drill-free dental implant. It's non-invasive, faster and more affordable than dental implants today and can be done by any family dentist. Our founding team has deep domain expertise and scaling experience.

Immunis is changing the course of immune-related diseases and ageing. Immunis is a private biotechnology company focused on the development of treatments for age-related and disease-related immune deficits. Immunis has developed a novel method to grow human stem cells for clinical use, and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modulation, and health.

Immunophotonics (JLabs @ TMC) is a developing a drug that turns a common tumor ablation into an immunotherapy for cancer. 

InfoBionic is an emerging mHealth company with a cloud based solution, MoMe(TM), for comprehensive remote physiological monitoring with a focus on Arrhythmia Detection. Our vision is to be part of the transformation of healthcare delivery by providing anywhere anytime access to cardiac monitoring with higher quality and lower cost with a new business model. MoMe(TM) has a clear regulatory path 510(k) and reimbursement in place.

InvVax is commercializing the world's first universal influenza vaccine. We mapped the entire flu genome. Over three years, the founder Arthur Young tediously went through all 13,000 nucleotide positions and generated a comprehensive map of the genome through a functional screen. We used the map to identify the 28 regions of the virus that cannot mutate without it self-destructing. InvVax's key differentiator is that our vaccine targets only invariant positions. Our direct competitors are targeting conserved regions only. These are regions of the virus that are the same between most flu strains in nature. Targeting conserved regions addresses the first problem with seasonal vaccines, the mismatch of predicted and circulating strains. But it does nothing to address the second main problem, the mutation of the virus. Our functional screen revealed that the majority of conserved residues are actually not invariant. These invariant regions and the screening methodology used to identify them are patent-pending. InvVax has secured an exclusive option on this technology from UCLA. In addition, we are developing a much broader patent strategy with Wilson Sonsini.

Kickstart is a wearable rehabilitation device designed to help you regain walking ability and accelerate functional improvements, both in daily life and in physical therapy. If you’re recovering from a stroke, spinal cord injury, or have a neurological condition such as multiple sclerosis and need help to maintain your mobility, Kickstart is made specifically to help you walk again and rediscover a more independent lifestyle. Use Kickstart to: Enable walking and improved independence, at home and in the community Enhance endurance, balance and control for walking and standing Guide correct gait patterns and reduce compensations Improve stability and alignment

Leo Lens solves the glaucoma treatment problem with a non-invasive automatic dosing weekly therapy which helps limit the progression of the disease and helps protect sight. With its MediPrint technology and proven execution team in place, Leo Lens can create significant value from a $2M Seed round advancing to Phase 3 clinical trials.

Lucirix is a new, mobile, patient-centric platform that gives physicians the ability to instantly collaborate with their colleagues from anywhere just like they were in a room together. Lucirix was designed by doctors to alleviate the frustration associated with communicating with consulting physicians. The trail of voicemail, medical assistants, and pager calls is replaced by a secure, mobile, SMS-like workflow tool that improves satisfaction for care providers and their patients.

Lumoptik is a medical device company that has developed the BrightPointTM needle guidance system to assist physicians with needle placement during epidural procedures for childbirth, spine/back pain and surgical procedures such as knee and hip replacements. Over 11 million epidural procedures are performed in the US each year. The large majority of these procedures are performed free hand by physicians with no mechanical or electronic needle guidance. Complications are common.

LynxBio's cytomics-based platform technology, MicroC3™, rapidly measures the therapeutic response of patients' own blood cancer cells to drugs. MicroC3™ seamlessly integrates into the clinical workflow and provides physicians with actionable results within 72 hours of a standard-of-care biopsy.

 Makucell is a new life science company that utilizes an innovative proprietary regenerative medicine technology to address aging skin, hair and nails in an entirely new way. Using a patent-pending new molecule, Asymmtate™, Makucell has developed non-prescription products that work with the skin’s own stem cells to produce healthier and more youthful appearing skin. Makucell is introducing the Renewnt™ (pronounced “Re-new-int”) brand of products based on its proprietary technology. Makucell was founded in September 2010 by distinguished researcher Michael Kahn, Ph.D., and colleagues at the Eli & Edythe Broad Center for Stem Cell and Regenerative Medicine at the University of Southern California Keck School of Medicine. The Makucell founders and industry experienced management team have a passion for utilizing the company’s core technology to develop new applications directed toward the challenges of aging and photoaging.

MatriSys Bioscience, Inc., a clinical stage Skin Microbiome Development company. Prof. Richard Gallo, UCSD Dermatology Chief, co-founder, SAB head, and a world leader in the use of microbes as novel medicines. NIH funded microbiome Phase I/II clinical program in Atopic Dermatitis (“AD”) market with 15 M US patients. 6 Partner discussions underway today, in diligence

Mechanodontics is a revolutionary method that can be used instead of braces or aligners that moves the teeth independently. Placed behind the teeth so they cannot be seen, this method reduces the treatment time to half and the number of visits to orthodontist to a quarter.

Mission Bio provides diagnostic tools that enable the full power of precision medicine. Cancer is driven by genetic differences among cells, and bulk analysis overlooks valuable information. Our tools analyze every cell in a sample, pinpointing the needle in the haystack to provide actionable information for selecting treatment.

myLAB Box is a first-of-its-kind service that delivers STD screening solutions to your doorstep. Uncomplicate your life today and get results with a click! Sign up for myLAB Box and enjoy the freedom to screen any time anywhere.

Neural Analytics is creating products and services to measure, diagnose and track brain health. Our current focus is on Traumatic Brain Injury (TBI). We combine leading edge data science with established hardware to allow first responders and clinicians to accurately assess mild to severe TBI, including concussions. Our devices are portable, reliable and produce precise and objective physiological measurements.    

Nocimed is a Google Chrome browser cloud/SaaS app to image pain by measuring chemical pain biomarkers using existing MR spectroscopy capabilities of leading MR scanners. 1st Focus: painful disc Dx for discogenic low back pain, replace discogram. Major strategic partnerships w/ leaders in radiology (Siemens) & spine (NuVasive).

Numira Biosciences, Inc., a contract research organization, provides imaging services for disease research, drug discovery, and pre-clinical studies in animal models. It offers Virtual Histology for soft tissue imaging applications, such as atherosclerosis, osteoarthritis, heart defects, pulmonary diseases, developmental biology, and phenotyping; and high-resolution bone imaging tools to analyze and characterize the skeletal anatomy and bones of animal models. The company also provides image processing and visual analytics solutions; AltaViewer visualization software, a visualization tool for use in non-clinical environments to view, manipulate, and export images of small animal datasets for research purposes; and imaging chamber, a multi-modality imaging chamber that facilitates the co-registration of anatomical and functional images by means of sequential multi-modal imaging.

NuvOx Therapeutics (aka NuvOx Pharma) focuses on diseases where hypoxia (lack of oxygen) plays critical roles. Hypoxia weakens effectiveness for cancer treatments and causes brain death in stroke. Our product is the first material to reverse tissue hypoxia.

Octagon is developing targeted drugs for severe autoimmune diseases that spare healthy immune functioning.

Orthera has been producing high-quality orthotic footwear for the medical market since 2001. Taking inspiration from the needs of professional athletes, Olympians and members of the U.S. military, Orthera orthotic inserts are optimized to perform for a wide array of lifestyles and needs. Whether you’re looking for peak performance or just want to feel comfortable as you walk and work, Orthera products help individuals take on each day without thinking about their feet, knees and backs. We blend our knowledge of biomechanical engineering with input from expert podiatrists, to provide you with superior orthotic inserts. Made with precise attention to detail in our San Diego, California factory, using the best materials possible, Orthera orthotic inserts are firm, supportive and easy to use. Orthera orthotic inserts are designed to help prevent foot and body damage, help athletes perform at the highest level of efficiency, and help to relieve common foot, knee and back pain. Orthera appreciates that your feet are the foundation for your whole body and your whole life. As such, our products are intended to help you stay active and healthy for life. Whether you use your Orthera orthotic inserts in dress shoes, running or tennis shoes or even sandals, you’ll be leveraging over a decade of research and development in foot health and comfort. Constructed in different designs and sizes, everyone can find an orthotic insert to fit their needs.

Oxeia Biopharmaceuticals is a clinical stage company developing ghrelin as a treatment for concussions and other neurotrauma indications. This is a phase 2 ready program with nearly 350 patient safety database and cGMP supply. Oxeia expects to have clinical data within 18 months of trial start. US Unmet need: > 3 M concussions per yr.

Pathware: 20% of biopsies fail to make a diagnosis. Each repeated procedure costs hospitals $3,000 per occurrence that is unreimbursed. Pathware has developed a biopsy quality assessment tool to verify the sample during the procedure to remove this risk while generating additional revenue for the hospital through established billing codes.

Treat the cause, not the symptoms. Flyte® is the only at-home intravaginal device that delivers the proven therapeutic treatment modality of mechanotherapy to treat stress urinary incontinence and strengthen the pelvic floor. Flyte® is the first and only treatment of its kind. Lydia Zeller CEO https://flytetherapy.com/

PercAssist - The disparity between donors and heart transplant recipients is growing at a very fast rate with the aging population. We provide a simple, cost-effective, minimally invasive approach, bridge to transplant, designed for interventional cardiologists to treat congestive heart failure.

PetDx is a molecular diagnostics startup focused on the development of breakthrough non-invasive “liquid biopsy” tests for the early detection, characterization, and management of cancer in pets. Founded by Daniel Grosu, former CMO of Illumina and Sequenom. PetDx is initially focused on the leading cause of death in dogs: cancer.

PharmaSecure’s innovative solutions were originally proven in the Pharmaceutical industry, protecting patients from the threat of counterfeit medicines. Counterfeit medicines are a global, multi-billion dollar epidemic that affects patients, public health, and the global healthcare system. Worldwide sales of counterfeit medicines account for an estimated $75 billion in annual sales and are responsible foran estimated 1 million annual deaths according to the World Health Organization. In emerging markets, the threat of counterfeit medicines and other products is even greater as supply chains are not as developed and regulatory bodies have not yet evolved to completely solve the problem. PharmaSecureis the leading provider of anti-counterfeiting solutions for emerging markets and has now protected over 1.8 billion products and counting by enabling patients and consumers to verify the authenticity of their products with a simple SMS, mobile app, or website. With a proven solution in the pharmaceutical industry, PharmaSecure has now expanded its innovative brand protection platform to be used in a wide-range of industries including FMCG, beauty & personal care, electronics, automotive, and agri-business. In addition to empowering consumers and patients to fight the spread of counterfeit goods, PharmaSecure’sconsumer engagement solutions can be used by companies to connect with their consumers and patients and offer an innovative ecosystem with direct communications, promos, and other interactive solutions. These solutions build a consumers’ connection to the brand, promote peace of mind against counterfeiting, and generate actionable consumer insights that are used by leading companies to improve marketing and sales performance. PharmaSecure has protected 1.8 billion products in 40+ geographies [...]

RealSeq Biosciences Where Efficiency Meets Accuracy. RealSeq’s industry leading small RNA NGS library technology allows broad detection with “best in class” low bias. Our wide range of sequencing services includes library preparation from extracted RNA or ready-to-sequence pooled libraries as well as customization for your bioinformatic needs. Contact us for more information to see how we can help with your RNA sequencing needs.

RegeneMed accelerates the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. Our patented, proprietary, core technologies enable in vitro growth of engineered human tissues, including liver, GI tract, bone marrow, blood-brain barrier, cardiovascular and neuronal. The first and critical application of these tissue-based in vitro model systems is to replace cell-based assays and animal testing to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the  pharmaceutical industry. RegeneMed tissue technologies are off-the-shelf available, scalable, reproducible and specific and designed to provide normal, diseased and polymorphic tissues. Additional applications include drug discovery platforms (cancer and antiviral), biosensors (chem/biowarfare), diagnostics, medical devices (extracorporeal devices) and tissue implants. RegeneMed provides 3-D human and animal liver tissue co-cultures, industry-standard monolayer cell-based products from the same donor for comparison, stem cells and 3-D tissue derived from stem cells, specialized tissue and stem cell media, customized reagents for drug discovery, and contract testing services for ADMET and efficacy assessment in drug discovery.  

Reglagene is a therapeutics company that leverages its expertise in the design and development of brain penetrant medicines to create breakthrough therapies for the safe and effective treatment of brain diseases.

Respiratory Motion’s ExSpiron 1Xi Minute Ventilation Monitor is the only product to measure respiratory volumes non-invasively. The ExSpiron 1Xi provides this comprehensive information for non-intubated patients for a more complete and quantifiable patient assessment throughout the care continuum. The ExSpiron 1Xi™ Non-Invasive Minute Ventilation Monitor is a continuous, point-of-care system that provides real-time quantitative monitoring of Minute Ventilation (MV), Tidal Volume (TV) and Respiratory Rate (RR). The ExSpiron 1Xi™ is the first monitor to provide these comprehensive metrics — previously only available for patients on a ventilator — for all patients. The ExSpiron 1Xi™ brings the vigilance and safety of cardiac monitoring to respiratory care, for a more complete and quantifiable patient assessment.

Sentrian's team of world-renowned clinicians, mathematicians, scientists, engineers and healthcare executives are building a next-generation remote patient analytics and monitoring platform with the goal to detect changes in a patient’s health state days, weeks and eventually months in advance. With these predictions it becomes possible to act on these changes before a significant health problem develops so that less risky, and lower cost, interventions can be implemented. This will help “at-risk” healthcare organizations make significant reductions in cost while allowing them to improve quality and alleviate an unquantifiable amount of human suffering. The Jointly Health end-to-end Remote Analytics and Monitoring Platform (RAMP) is designed to continuously identify patients in need of remote monitoring, enable the development of health deterioration detection models, and deploy these models to monitor patients and detect early deterioration before symptoms manifest themselves.

Single Pass is the only patented, disposable, electrocautery device that can cauterize deep tissue through a guide needle. The Single Pass electro-cautery device effectively seals the biopsy channel by cauterizing the tissue to prevent bleeding. It also improves the safety of biopsy procedures for at-risk patients and allows for the use of larger guide needles to collect bigger tissue samples with a fewer number of needle passes. Safe. Fast. Effective.

Snap Bio is developing novel treatments for pancreatic cancer and other endodermal cancers based on next generation kinase inhibitors derived from Nature. Snap Bio implements a novel approach and cutting edge platform to transform natural molecules into potent and selective inhibitors of PIM3 kinases linked to these deadly diseases.

At Solulink, we develop high-performance products that link biomolecules together. Our continuous efforts in new product development and service offerings enable you to remain at the forefront of advanced bioscience research. Our products are developed with you in mind. As we refine our products and develop new ones, we continue to link up with researchers to help guide our development. Milestones such as the NanoLink™ or MagnaLink™ Streptavidin Magnetic Beads with the highest available binding capacity, ChromaLink™ Antibody Labeling Kit and the antibody-oligo conjugation versions of our kits represent our commitment to consistently providing innovative products to meet the changing needs of our customers. We are continually adding more user-friendly features to our linker capability and kits. We are now the first company offering complete antibody labeling kits with purification included. And we are developing more exciting new conjugation kits, all based on the same successful product ideals: Versatile products that are easy to use, quantitative and affordable. Bioconjugation technologies, enabling the linking of biomolecules to reporters, surfaces, or other biomolecules, constitute a key tool kit enabling many classes of reagents which power modern biotechnologies such as flow cytometry, immunohistochemistry (“IHC”), Enzyme-Linked Immunosorbent Assay (“ELISA”), Western blotting, next generation sequencing, gene expression microarrays, bead-based cell isolation and multiplexed assays, and bioactive surfaces. But even as biotechnology’s need for higher-performance conjugation chemistries grows ever greater, bio-linking technologies have largely stagnated following the introductions of the unstable and unreliable streptavidin/biotin and maleimide chemistries for protein conjugation in the 1960s.

The Holmed Swivel Port System and full line of Spine Instruments, marketed and distributed globally by Spine Surgical Innovation, are designed for ease of use, high quality and high value. Elegant in its simplicity, intuitive in its design, the patented Swivel Port System and associated instruments for minimally invasive surgery provides simple, safe and easy tools that compliments your existing surgical technique. Offering the Minimum Incision, Maximum Sight Approach, with maximum “ sight” and visualization, the Swivel Port unique design fends off disruptive and time consuming “muscle creep” so common with tubular retractor systems. This comprehensive system has grown to six different sets of working ports configured and sized for both posterior and lateral lumbar approaches, including two new systems designed for posterior cervical procedures. For over two decades our designs are surgeon driven, our rich history and culture is focused on making surgical instruments and systems safe, easy to use and cost effective. We look forward to working with you in the near future to help support your objective review, evaluation and consideration of these truly innovative systems and instruments.

TEGA is developing bioengineered heparin as an alternative to the current supply of heparin, 100% of which comes from pig intestines intestines and 80% of which comes from slaughterhouses in China. TEGA is also developing conjugates that enhanced the delivery of enzyme replacement therapies to the brain for Lysosomal Storage Disorders

Fetal motion predicts healthy birth outcomes.  Tiny Kicks, LLC develops a wireless smart sensor system that captures fetal movement with machine learning to predict and guide healthy pregnancy outcomes. The band aid like sensor consists of soft strain sensors and Bluetooth to send data to mom's phone. TK's passive sensor emits no unsafe energy.

Tourmaline Labs - an AI Tech Company, is revolutionizing mobility, driver data insights and interpretation by recording billions of events via smartphone (or other data sources). With an easy-to-deploy SDK/API, the open platform enables companies to manage their shared economy fleets, improving efficiency, driver behavior and vendor selection.

Trials.ai leverages artificial intelligence to accelerate clinical trials management - because patients don’t have time to wait

TRIO = TOXICITY REDUCTION IN ONCOLOGY TRIO = TERMINATING RESISTANCE IN ONCOLOGY TRIO Pharmaceuticals, Inc. is a cancer immunotherapeutics company pioneering dual action drugs to generate immunogenic tumors. TRIO's innovative antibody drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. TRIO is developing a proprietary platform of dual action tumor immunity enhancing drugs aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells. TRIO has an experienced team that has developed first-in-class FDA-approved drugs. Contact us.

J3 Bioscience, Inc. develops an intravaginal ring (IVR) product, VR101, for the treatment of vaginal dryness using ViroPan’s proprietary vaginal delivery technology. The company was formerly known as Viropan, Inc.

Visgenx is developing therapeutics for Age-Related Macular Degeneration a condition with no approved products and affecting > 196 million worldwide. The therapeutics are based on restoring the age-related dysfunction in the gene underlying the disorder. Our products include a fast to market repurposed drug and a gene therapy solution.

Visicell, “GPS for cell therapy”, provides non-invasive, imaging-based solutions to customers in a multi-billion dollar cell therapy industry. Our patent-pending solutions track therapeutic cells in the body and arm our users with rapid clinical information allowing for timely decision making on treatment strategy for better patient care.